SARS-CoV-2 spike protein fusion transformation: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Eric Martz, Karsten Theis

Revision as of 03:34, 12 August 2020 view source Eric Martz (talk \| contribs) ConfirmAccount, Editor, Tester, Administrators 27,351 edits No edit summary ← Older edit		Revision as of 03:35, 12 August 2020 view source Eric Martz (talk \| contribs) ConfirmAccount, Editor, Tester, Administrators 27,351 edits No edit summary Newer edit →
Line 175:		Line 175:


	The larger interior cavity opens to the surface when [[SARS-CoV-2_protein_S_priming_by_furin\|one receptor binding site is extended]]. The smaller interior cavity seems crucial to fusion function. Many fusion inhibiting drugs have been found to bind ~~to the analogous~~ smaller cavity in related proteins, and escape mutations have clustered in or near this cavity<ref name="romeo" />. Using virtual screening simulations, Romeo, Iacovelli & Falconi<ref name="romeo">PMID: 32565126</ref> identified available drugs that seem likely to block the fusion transformation by binding in the smaller cavity.		The larger interior cavity opens to the surface when [[SARS-CoV-2_protein_S_priming_by_furin\|one receptor binding site is extended]]. The smaller interior cavity seems crucial to fusion function. Many fusion inhibiting drugs have been found to bind within a similar smaller cavity in related proteins, and escape mutations have clustered in or near this cavity<ref name="romeo" />. Using virtual screening simulations, Romeo, Iacovelli & Falconi<ref name="romeo">PMID: 32565126</ref> identified available drugs that seem likely to block the fusion transformation by binding in the smaller cavity.